Premium
Impact of human papillomavirus and smoking on survival outcomes after transoral robotic surgery
Author(s) -
Stucken Chaz L.,
de Almeida John R.,
Sikora Andrew G.,
Tong Charles C. L.,
Genden Eric M.
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23915
Subject(s) - medicine , transoral robotic surgery , human papillomavirus , neck dissection , oncology , head and neck squamous cell carcinoma , radiation therapy , basal cell , head and neck cancer , carcinoma , surgery
Abstract Background The purpose of this study was to evaluate oncologic outcomes of head and neck squamous cell carcinoma (HNSCC) treated with transoral robotic surgery (TORS) based on human papillomavirus (HPV) and smoking risk factors. Methods Fifty‐five patients with HNSCC treated with TORS, neck dissection, +/‐ adjuvant chemotherapy, and/or radiation therapy were retrospectively analyzed based on HPV and smoking status. Results Smokers and nonsmokers had locoregional control rates of 96.3% and 94.4% ( p = .66) and progression‐free survival rates 83% and 94.1% ( p = .09), respectively. HPV‐negative and HPV‐positive patients had locoregional control rates of 87.1% and 100% ( p = .03) and progression‐free survival rates of 74.2% and 95.2% ( p = .01), respectively. Locoregional control rates for HPV‐negative smokers, HPV‐negative nonsmokers, HPV‐positive smokers, and HPV‐positive nonsmokers were 90.9%, 80.0%, 100%, and 100% ( p = .18), whereas progression‐free survival rates were 72.2%, 80.0%, 92.3%, and 100% ( p = .04), respectively. Conclusion HPV status may be more important than smoking status in determining the risk of disease recurrence and death in patients treated with TORS. © 2015 Wiley Periodicals, Inc. Head Neck 38: 380–386, 2016